ovarian-cancer

Documents about ovarian-cancer

• Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine#651122ClinicalTrials.gov
• Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma#813566ClinicalTrials.gov
• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#481734ClinicalTrials.gov
• ASk Questions in GYnecologic Oncology (ASQ-GYO)#827641ClinicalTrials.gov
• Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses#888924ClinicalTrials.gov
• Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#880380ClinicalTrials.gov
• Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes#858555ClinicalTrials.gov
• Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer#884734ClinicalTrials.gov
• Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation#867817ClinicalTrials.gov
• T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer#172290ClinicalTrials.gov
• Rate and risk factors of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer: a retrospective analysis from a referral center#445714IRIS
• Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy#811385ClinicalTrials.gov
• A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer#825315ClinicalTrials.gov
• Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer#877215ClinicalTrials.gov
• Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer#889628ClinicalTrials.gov
• Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer#914977ClinicalTrials.gov
• Guangzhou Women's Health Cohort Study (GWHCS)#146323ClinicalTrials.gov
• Taiwan Cancer Moonshot Project#853905ClinicalTrials.gov
• Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup#677249HAL (France)
• A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer#862362ClinicalTrials.gov
• A Study of SGN-ALPV in Advanced Solid Tumors#887264ClinicalTrials.gov
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer#833149ClinicalTrials.gov
• Autoantibodies as biomarkers for ovarian cancer#129205PMC Full-Text (OAI)
• Hyperthermic intraperitoneal chemotherapy in Ovarian cancer#955319Koc University Digital Collections
• Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)#813355ClinicalTrials.gov
• Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer#860522ClinicalTrials.gov
• Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors#802430ClinicalTrials.gov
• Anoikis Resistance and Metastasis of Ovarian Cancer Can Be Overcome by CDK8/19 Mediator Kinase Inhibition#331562Scholar Commons
• Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study#665182HAL (France)
• A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)#827893ClinicalTrials.gov
• Genetic Education in BRCA Families#838961ClinicalTrials.gov
• A Study of Long-Term Responders on Olaparib#867373ClinicalTrials.gov
• Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer#879087ClinicalTrials.gov
• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer#896906ClinicalTrials.gov
• INSPIRE: a Multi-Cancer Early Detection Study#854463ClinicalTrials.gov
• Analyzing the Composition of Tears to Identify Cancer#838083ClinicalTrials.gov
• Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients#841306ClinicalTrials.gov
• LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer#870279ClinicalTrials.gov
• Cancer Loyalty Card Study 2 (CLOCS-2)#889575ClinicalTrials.gov
• Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer#825097ClinicalTrials.gov
• Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.#870344ClinicalTrials.gov
• ID Card of Mcl-1 PROTAC degrader: From in silico design to biological validation in chemoresistant ovarian cancer#280401HAL (France)
• Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences#813081ClinicalTrials.gov
• Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland#880290ClinicalTrials.gov
• Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency#882344ClinicalTrials.gov
• ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease#955619Koc University Digital Collections
• Secondary cytoreduction for ovarian cancer relapse: results from the high surgical quality, multi-center "Surgery in Recurrent Ovarian Cancer Research Consortium (SURROC-CON)"#965591Bielefeld Pub
• Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer#889982ClinicalTrials.gov
• Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer#916573ClinicalTrials.gov
• PET-CT vs. Integrated MR-PET Scanning of GYN Cancers#909977ClinicalTrials.gov